Evidence map›Paper›PMID 25499804›Full record

ArticleDiagnostic pathology2014

Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors.

Mutsuko Omatsu, Toshiaki Kunimura, Tetsuya Mikogami, Akira Shiokawa, Tomoko Nagai, Atsuko Masunaga, Akihiko Kitami, Takashi Suzuki, Mitsutaka Kadokura

Open access · goldAbstract readComparative Study
In one paragraph

Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Thymic Epithelial Tumors: An Evolving Field.Life (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Cancer-Associated Myeloid Regulatory Cells.Frontiers in immunology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mutsuko OmatsuDepartment of Clinico-diagnostic Pathology, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki-ku, Yokohama, 224-8503, Japan. m.omatsu@med.showa-u.ac.jp.
Toshiaki KunimuraDepartment of Clinico-diagnostic Pathology, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki-ku, Yokohama, 224-8503, Japan. kunimura@med.showa-u.ac.jp.
Tetsuya MikogamiDepartment of Clinico-diagnostic Pathology, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki-ku, Yokohama, 224-8503, Japan. mikogami1971@yahoo.co.jp.
Akira ShiokawaDepartment of Clinico-diagnostic Pathology, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki-ku, Yokohama, 224-8503, Japan. shiokawa@med.showa-u.ac.jp.
Tomoko NagaiDepartment of Clinico-diagnostic Pathology, Showa University School of Medicine, Tokyo, Japan. tomo@med.showa-u.ac.jp.
Atsuko MasunagaRespiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. nonkoamesho0324@yahoo.co.jp.
Akihiko KitamiRespiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. akitami@med.showa-u.ac.jp.
Takashi SuzukiRespiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. suzuki.t@med.showa-u.ac.jp.
Mitsutaka KadokuraDivision of Thoracic and Cardiovascular Surgery, Department of Surgery, Showa University School of Medicine, Tokyo, Japan. kadokura@med.showa-u.ac.jp.
Showa University · JPShowa University Northern Yokohama Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn a number of human malignancies, tumor-associated macrophages (TAMs) are closely involved in tumor progression. On the other hand, dendritic cells (DCs) that infiltrate tumor tissues are involved in tumor suppression. However, there have been very few reports on the distribution profiles of TAMs and DCs in thymic epithelial tumors. We examined the difference in the distribution profiles between TAMs and DCs in thymoma and thymic carcinoma.

methodsWe examined 69 samples of surgically resected thymic epithelial tumors, namely, 16 thymic carcinomas and 53 thymomas, in which we immunohistochemically evaluated the presence of TAMs using CD68 and CD163 as markers and DCs using S100 as the marker in tumor tissue samples in comparison with normal thymic tissues.

resultsThe percentage of samples with a large number of CD68+ TAMs was not significantly different between thymic carcinoma and thymoma (7/16 versus 16/53, p = 0.904). However, the percentage of sample with a large number of CD163+ TAMs was significantly higher in thymic carcinoma than in thymoma (15/16 versus 34/53, p = 0.024). In contrast, the percentage of samples with a large number of S100+ DCs was significantly lower in thymic carcinoma than in thymoma (2/16 versus 23/53, p = 0.021).

conclusionsTo the best of our knowledge, we are the first to show a high percentage of CD163+ TAMs and a low percentage of S100+ DCs in thymic carcinoma samples, and our findings may provide an idea for future targeted therapeutic strategies for thymic carcinoma using antibodies that inhibit monocyte differentiation to TAMs, thereby skewing TAMs differentiation toward DCs. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_215.

Indexed as

AdultAgedAged, 80 and overAntigens, CDAntigens, Differentiation, MyelomonocyticCase-Control StudiesCD163 AntigenDendritic CellsFemaleHumansImmunohistochemistryMacrophagesMaleMiddle AgedNeoplasms, Glandular and EpithelialReceptors, Cell SurfaceAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenReceptors, Cell SurfaceS100 Proteins

Identifiers

PMID25499804
PMCPMC4302590
OpenAlexW2103662870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.